SUBSCRIBE
SUBSCRIBE
News   Drug Development

Repros Therapeutics Inc. Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal® Clinical Program

January 7, 2013 | 
1 min read

THE WOODLANDS, Texas, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a clinical update of its Androxal® Phase 3 program.

Clinical research Phase III
MORE ON THIS TOPIC
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
Cancer
GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A player checkmates the king, target in the background, chess game and strategy concept, vintage style poster
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An Eli Lilly Research Laboratories sign/
Cancer
Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac